These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 18642974

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S.
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [Abstract] [Full Text] [Related]

  • 3. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H.
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.
    Ikai S, Suzuki T, Mimura M, Uchida H.
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):4003-4010. PubMed ID: 27631410
    [Abstract] [Full Text] [Related]

  • 7. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics.
    Uchida H, Graff-Guerrero A, Mulsant BH, Pollock BG, Mamo DC.
    Schizophr Res; 2009 Apr; 109(1-3):130-3. PubMed ID: 19179049
    [Abstract] [Full Text] [Related]

  • 13. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L.
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.